Perioperative and oncologic outcomes with robotic vs. open radical prostatectomy
A population-based study in Ontario, Canada
DOI:
https://doi.org/10.5489/cuaj.9708Keywords:
Prostate cancer, Robotic surgery, Radical prostatectomy, Oncologic, Functional and Complications OutcomesAbstract
Introduction: Robotic-assisted radical prostatectomy (RARP) is the predominant surgical treatment for localized prostate cancer worldwide, but adoption has been slower in Ontario due to funding constraints. This setting enables population-level comparison of RARP and open radical prostatectomy (ORP). We evaluated perioperative and short-term oncologic outcomes for men undergoing radical prostatectomy in Ontario between April 2017 and March 2024.
Methods: We conducted a retrospective cohort study of all patients who underwent publicly funded radical prostatectomy for localized prostate cancer. Co-primary outcomes were blood transfusion rates and hospital length of stay (LOS). Secondary outcomes included operative time, 30-day readmission, vesico-urethral anastomosis stenosis (VUAS) requiring intervention, surgical wait time, and travel distance. Exploratory outcomes included 30-day mortality, positive surgical margins (PSM), and receipt of pelvic radiation post-prostatectomy.
Results: Among 15 073 patients, 6645 (44.1%) underwent RARP and 8428 (55.9%) ORP. Median followup was 36.8 months after RARP and 38.8 months after ORP. RARP was associated with lower transfusion rates (1.2% vs. 4.7%, p<0.001), shorter LOS (median 1.0 vs 2.0 days, p<0.0001), fewer 30-day readmissions (23.6% vs. 26.1%, p=0.0005), and markedly fewer VUAS interventions (1.2% vs. 12.0%, p<0.0001). RARP had longer adjusted operative time (+60 minutes, p<0.001), longer waits, and greater travel distance. PSM (31.0% vs. 38.2%, odds ratio 0.72, p<0.001) and need for post-prostatectomy radiotherapy (20.9% vs. 29.5%, hazard ratio 0.65, p<0.0001) were lower with RARP.
Conclusions: In Ontario, RARP demonstrated superior perioperative outcomes, lower VUAS, and improved oncologic indicators compared with ORP. As access expands, balancing quality, equity, and timeliness will be essential, alongside further study of cost implications.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:
- Post the Article on any Web site
- Translate or authorize a translation of the Article
- Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
- Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.
The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.
You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.
The CUA also requires you to warrant the following:
- That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
- That all individuals who have made a substantive contribution to the article are acknowledged;
- That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
- That the Article does not libel or violate the privacy rights of any third party.



